

Subject Index

A

- Acidosis, brain edema, 627
- Acipimox, suppression of nonesterified fatty acid levels, 1400
- Adhesion molecules, elevated level in insulin-dependent diabetes mellitus, 1668
- Adipose tissue, lipolysis control, prostaglandin E₂, 927
- Adenosine deaminase locus, mutations, 1640
- Adoptive transfer, prevention by prophylactic insulin, 1273
- Advanced glycosylation end products aminoguanidine action, 26 interaction with macrophages, (Suppl. 2) 52
- pentosidine as Maillard reaction marker, 1286
- Aging
 - glucose counterregulation, 671
 - islet cell antibodies, 1022
 - thyrogastic antibodies, 1022
- Albumin glycation, effects on glomerular basement membrane permeability, 1415
- Albuminuria, angiotensin-converting enzyme action, 62
- Aldose reductase, mesangial cells, 1165
- Alloxan-induced diabetes mellitus, brain D1 dopamine receptor, 1119
- Ambulatory blood pressure, insulin-dependent diabetes mellitus, 1035
- American Diabetes Association Council on Complications, Macrovascular Complications Symposium, (Suppl. 2) 116
- β -amino acid carrier, taurine transport adaptation, 1130
- Aminoguanidine
 - effects on neuropathy, 47
 - inhibition of advanced glycosylation end products, 26
 - potential therapeutic use, 897, (Suppl. 2), 57
 - prevention of vascular dysfunction, 552
- Amylin
 - effect on carbohydrate metabolism, 975
 - expression, obesity, 685
 - secretion
 - fasting effects, 508
 - hyperglycemia effects, 723
 - hypoglycemia effects, 508
 - pancreatic β -cell line, 1409
- Angiotensin II, regulation of renin secretin, 1100

- Animal models. *See* Dogs; Guinea pigs; Hamsters; Mice; Monkeys; Rats
- Anti-CD3 immunotoxin, diabetes prevention, 457
- Apolipoprotein
 - A-I, reverse cholesterol transport, (Suppl. 2) 81
 - B-containing, identification of, (Suppl. 2) 18
 - E, role in atherosclerosis acceleration, (Suppl. 2) 77
- Arachidonic acid metabolism, inhibitors, effects on insulin release, 620
- Aspirin, effect on platelet aggregation in insulin-dependent diabetes mellitus, 261
- Atherosclerosis
 - apolipoprotein E/lipoprotein lipase effects, (Suppl. 2) 77
 - cytokines effects, (Suppl. 2) 97
 - lipoprotein
 - glycemic control effects, 1301
 - levels, (Suppl. 2) 86
 - oxidation, (Suppl. 2) 61, 74
 - Maillard reaction, (Suppl. 2) 36
 - pentosidine levels, 153
 - plasminogen-plasmin system changes, (Suppl. 2) 32
- ATP-sensitive K⁺ channels, glucose sensitivity, 861
- Atrial natriuretic peptide
 - effect on glomerular filtration rate, 533
 - effect on renal plasma flow, 533
 - insulin-dependent diabetes mellitus, sodium retention, 936

B

- Basic fibroblast growth factor, 222
- Black
 - Americans, non-insulin-dependent diabetes mellitus
 - glucokinase gene as marker, 843
 - insulin gene, 742
 - Caribbeans, insulin resistance syndrome, 1385
- Blood coagulation changes, (Suppl. 2) 32
- Body fat distribution, glucose metabolism, 1151
- Bone marrow transplantation, islet allograft survival, 771
- Brain
 - D1 dopamine receptor, 1119
 - edema, insulin-dependent diabetes mellitus, 627
 - metabolism, hypoglycemia, 557

C

- C-peptide
 - clearance after kidney-pancreas transplantation, 1346
 - estimation of insulin secretion rate, 368
- Ca²⁺
 - entry, human β -cell function, 662
 - influx, insulin release, 438
 - role of cytosolic, 1555
- Captopril, inhibitory effect on albuminuria, 62
- Carbohydrates
 - metabolism
 - amylin effect, 975
 - implantable insulin pumps, 657
 - non-insulin-dependent diabetes, effect on lipoproteins, 1278
- Cardiac sympathetic nervous dysfunction, measurement of [¹²⁵I]metaiodobenzylguanidine accumulation, 1069
- Cardiovascular disease
 - HbA_{1c}, 202
 - Lp(a) levels, 1267
 - women, hyperglycemia, 202
- Cataractogenesis, Maillard reaction, (Suppl. 2) 36
- Catecholamine release, insulin secretion inhibition, 1632
- β -cells
 - antigen macrophages, interaction with T-cells, 1380
 - autoimmunity, reduction by intrathymic islet cell transplantation, 1672
 - destruction
 - nitric oxide effects, 897
 - T-cell differences, 998
 - function
 - Ca²⁺ entry, 662
 - insulin resistance, 1172
 - glucokinase as glucose sensor, 792
 - insulin secretion, electrical activity patterns, 1221
 - pancreatic
 - amylin secretion, 1409
 - heterogeneity, 777
 - tropin, concentration in non-insulin-dependent diabetes mellitus, 1160
- Central nervous system, diabetes effects, 557
- Children, insulin resistance, racial differences, 313
- Chinese, insulin-dependent diabetes mellitus susceptibility, DQA1 and DQB1 alleles, 914
- Cholesterol
 - glomerular dynamics, 286

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
February, 123-253
March, 255-399

April, 401-556
May, 557-656
June, 657-775

July, 777-895
August, 897-1027
September, 1029-1219

October, 1221-1365
November, 1367-1501
December, 1503-1676

reverse transport, apoA-I effects, (Suppl. 2) 81
 Choline acetyltransferase, marker for parasympathetic innervation, 160
 Chromosome 20, genetic mapping, MODY, 88
 Chylomicron metabolism, streptozocin-induced diabetic rats, 325
 Cognitive dysfunction
 insulin-dependent diabetes mellitus adults, 107
 hypoglycemic threshold, 392
 Collagen
 changes after nonenzymatic glycation, (Suppl. 2) 49
 glucose modification of, oxygen cross-linking effects, (Suppl. 2) 42
 Congenital malformations, *myo*-inositol level, 989
 Coronary heart disease
 nephropathy, 813
 Pima Indians, non-insulin-dependent diabetes mellitus, 1141
 risk factors, (Suppl. 2) 1
 Native Americans, (Suppl. 2) 4
 Corticotropin
 effect on glucose tolerance in dogs, 1446
 releasing factor, effect on glucose intolerance, 493
 Cytokines, effects on hyperlipidemia, (Suppl. 2) 97

 D1 receptor, alloxan-induced diabetes mellitus, 1119
 Denaturing gradient gel electrophoresis, gene mutation detection, 408
Diabetes, history of journal, 1
 Diacylglycerol, insulin receptor tyrosine kinase activity, 1373
 Diet
 carbohydrates
 high/low effect on lipoproteins, 1278
 non-insulin-dependent diabetes mellitus determinant, 484
 fat, non-insulin-dependent diabetes mellitus determinant, 484
 medium-chain triglycerides, glucose metabolism improvement, 641
 1,25-dihydroxyvitamin D₃, effect on insulin resistance, 1491
 Dogs
 glucose tolerance, epinephrine and corticotropin effects, 1446
 hypoglycemia, hepatic autoregulation, 1308
 indirect effects of insulin, 1188
 insulin, requirement of glucose delivery to liver, 1247
 islet transplantation, reduced β -cell function, insulin resistance, 1172

pancreatectomized, treatment with hybrid pancreas, 886
 Dopamine receptor, alloxan-induced diabetes mellitus, 1119
 DR2 haplotype, insulin-dependent diabetes mellitus susceptibility, 904
 Dyslipidemia, lipid-lowering therapy, (Suppl. 2) 111

E
 ECM gene expression, 1520
 Embryo development
 insulin action, 318
 insulinlike growth factor effects, 318
 Endothelial cells
 proinsulin, plasminogen activator inhibitor type-1, 890
 tissue plasminogen activator expression, 1009
 Endothelin-1, resistance to, retinopathy, 1533
 Environment, non-insulin-dependent diabetes mellitus determinant, 484
 Epinephrine
 delayed secretion, aging, 671
 effect on glucose tolerance in dogs, 1446
 Exercise
 glucose transporter content, skeletal muscle, 920, 1091
 insulin deficiency effect on glucose, 1229

F
 Fasting
 amylin secretion, 508
 insulin receptor expression/gene transcription, 1609
 insulin secretion, 508
 Fat, lactate production and pyruvate dehydrogenase activity in, 1547
 Forebrain ischemia, 1328
 Fourth International Workshop for Standardization of ICA Measurements, 1570
 Framingham Heart Study, HbA_{1c} and cardiovascular disease, 202
 Free fatty acids
 insulin receptor binding, 294
 tyrosine kinase activity, 294
 Free radicals, activity, microalbuminuria, 909
 French Caribbean Islands, insulin resistance syndrome, 1385
 Fructose transport, GLUT5, 1360

G
 Galanin, human, inhibition of insulin-secretion, 82

Gangliosides, effects on axonal transport in neuropathy, 866
 Gene
 expression, insulin action, 194
 mutation, insulin receptors, detection of, 408
 transcription, cellular pyruvate oxidation, 339
 Genetic mapping
 insulin-dependent diabetes mellitus, 1029
 MODY, 88
 non-insulin-dependent diabetes mellitus, 401
 Genetics
 ADA and GLUT2, MODY linkage analysis, 962
 insulin-dependent diabetes mellitus, 1029
 non-insulin-dependent diabetes mellitus
 Black Americans, insulin gene, 742
 determinant, 484
 glucokinase gene, 843, 1496
 inheritance, 416
 mutations, familial clustering, 850
 proliferative retinopathy markers, 879
 somatic therapy, transplanted cell removal, 956
 Gestational diabetes, skeletal muscle, gene expression of GLUT4, 465
 Glibenclamide, effect on ketone metabolism, 968
 Glomerular
 basement membrane permeability, albumin glycation effects, 1415
 capillary hydraulic conductivity, 1106
 dynamics, experimental diabetes, 286
 filtration rate
 atrial natriuretic peptide effects, 533
 nephropathy screening, 581
 prostacyclin effects, 533
 hemodynamics, renal functional reserve, 267
 mesangium, cell and matrix components, 679
 Glucagon
 immunoneutralization, urea synthesis normalized, 12
 reduced secretion, aging, 671
 Glucocorticoid, effect on GLUT4 level in skeletal muscle, 728
 Glucokinase
 gene, non-insulin-dependent diabetes mellitus
 linkage analysis, 1496
 marker for Black Americans, 843
 maturity-onset diabetes of the young, 1367
 glucose sensor of β -cells, 792
 human islet gene, 807
 Glucose
 collagen modification, oxygen cross-linking effects, (Suppl. 2) 42

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

counterregulation, effect of
hypoglycemia, 1597
decrease of GLUT1 protein, perineurial
cells, 1587
delivery to liver, insulin requirement,
1247
desensitization, 1555
high concentration
pericyte exposure, resistance to
endothelin-1, 1533
hypoglycemia
hepatic autoregulation, 1308
reduced hepatic production, 1335
induced insulin secretion, GLUT2 level,
1320
intolerance
corticotropin-releasing factor effect,
493
pathogenic factors, 1540
metabolism
hyperglycemia effect, 174
insulin deficiency effects, 1229
non-insulin-dependent diabetes
mellitus, medium-chain
triglycerides, 641
obesity, 698, 1151
oxidation, effects of oleate and insulin,
1063
regulation of
glucose transporters, 592
glucose transporter expression, 76
sensitivity, ATP-sensitive K⁺ channels,
861
tolerance
diurnal variation, 750
epinephrine and corticotropin effects
in dogs, 1446
hypertension, 872
visceral obesity, 826
transporter
colocalization, 766
GLUT4, 1436
GLUT5, 1360
insulin action, 227, 1063
insulin regulation, gene expression,
274
isoform expression in rat islets, 76
levels, non-insulin-dependent
diabetes mellitus, rodent
models, 187
liver, regulation of, 22
localization in rat soleus muscle, 215
oleate effects, 1063
regulation of by glucose, 592
role in insulin resistance, 728
skeletal muscle
exercise effects, 920, 1091
gene expression, 465
uptake
effects of oleate and insulin, 1063
indirect insulin effects, 1188
GLUT1
level, glucose regulation, 76
non-insulin-dependent diabetes
mellitus, linkage analysis, 1660

oleate and insulin effects, 1063
protein decrease, perineurial cells,
1587
GLUT2
colocalization in rat kidney, 766
level
glucose-induced insulin secretion,
1320
glucose regulation, 76
non-insulin-dependent diabetes
mellitus rodent models, 187
rRNA, regulation, 22
linkage analysis
MODY, 962
non-insulin-dependent diabetes
mellitus, 1660
mRNA, uptake activity, regulation of by
glucose, 592
GLUT4
gene characterization/variation, 1436
level
exercise effects in skeletal muscle,
920, 1091
non-insulin-dependent diabetes
mellitus rodent models, 187
skeletal muscle, 728, 1562
localization, rat soleus muscle, 215
oleate and insulin effects, 1063
skeletal muscle gene expression, 465
GLUT5, 1360
Glutamic acid
antibodies, insulin-dependent diabetes
mellitus screening, 548
decarboxylase
antibodies, insulin-dependent
diabetes mellitus marker, 782,
1182
isoforms, insulin-dependent diabetes
mellitus, 1355
T lymphocytes, 118
Glycerol, production and utilization,
obesity, 444
Glycogen synthase, impaired activation
of, non-insulin-dependent
diabetes mellitus risk factor, 598
Glycosylation
advanced, pentosidine as marker, 1286
protein, vitamin C effect, 167
G-proteins, hormonal inhibition of insulin
secretion, 1390
Growth
factors, insulin action, 194
hormone
binding protein, low level in
insulin-dependent diabetes
mellitus, 605
insulin action, 424
pituitary response, 17
resistance, insulin-dependent
diabetes mellitus, 605
skeletal muscle protein synthesis,
424
Guinea pigs, embryonic development,
318

H
Hamsters, glucose transporters,
regulation of by glucose, 592
Heart rate spectral analysis, autonomic
neuropathy, 633
Heat shock proteins, insulin-dependent
diabetes mellitus, 788
Homeostatic abnormalities,
microalbuminuria, 909
Hepatocytes
rats, free fatty acids effects, 294
regulation of glucose transporter, 22
HLA
alleles
DQA1 and DQB1, insulin-dependent
diabetes mellitus susceptibility,
914
DR2, insulin-dependent diabetes
mellitus susceptibility, 904
haplotypes, insulin-dependent diabetes
mellitus, 123
insulin-dependent diabetes mellitus
susceptibility heterodimer, 378
Human serum, measurement of
proinsulin, 1084
Hyperglycemia
brain edema, 627
cerebral taurine transport, 1130
congenital malformations, 989
effect on
amylin secretion, 723
ECM gene expression, 1520
glucose metabolism, 174
pituitary response to growth
hormone, 17
skeletal muscle glycogen synthase,
1453
vascular smooth muscle cells, 1464
forebrain ischemia, 1328
insulin-dependent diabetes mellitus,
insulin resistance, 571
insulin resistance, 274
prolonged, myo-inositol flux, 760
prostaglandin E₂ effect on embryo
anomalies, 1644
psychomotor slowing, 107
women, cardiovascular disease, 202
Hyperinsulinemia, insulin resistance, 274
Hyperlipidemia, cytokines effects, (Suppl.
2) 97
Hypertension
coronary heart disease, (Suppl. 2) 1
glucose tolerance, 872
syndrome X, 715
Hypoglycemia
amylin secretion, 508
forebrain ischemia, 1328
glucose counterregulation, 1597
hepatic autoregulation, 1308
iatrogenic, insulin-dependent diabetes
mellitus, 255
insulin-dependent diabetes mellitus,
cognitive dysfunction, 392
insulin secretion, 508

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
February, 123-253
March, 255-399

April, 401-556
May, 557-656
June, 657-775

July, 777-895
August, 897-1027
September, 1029-1219

October, 1221-1365
November, 1367-1501
December, 1503-1676

inhibition due to catecholamine release, 1632
neurochemistry, 557
reduced pituitary-adrenocortical hormonal secretion, 1335
risk factors, aging, 671
Hypomagnesemia, polyol theory, model for complications development, 35
Hypothyroidism, 147

I

ICA12, insulin-dependent diabetes mellitus risk identification, 183
ICA512, insulin-dependent diabetes mellitus risk identification, 183
IDDM. *See* Insulin-dependent diabetes mellitus
Impaired glucose tolerance, skeletal muscle, gene expression of GLUT4, 465
Incidence, thyroiditis, nonobese diabetic mice, 40
Inositol
glycan, insulin receptor tyrosine kinase activity, 1373
transport, magnesium action, 35
Insulin
deficiency, effect on glucose during exercise, 1229
ECM gene regulation, effect on, 1520
encapsulated, oral administration, 451
gene
expression, 194
non-insulin-dependent diabetes mellitus, Black Americans, 742
obesity, 685
glucose turnover, 1188
GLUT4 translocation in skeletal muscle, 1562
growth factors, 194
human, degradation, 539
indirect effects, 1188
levels, visceral obesity, 826
mediator, non-insulin-dependent diabetes mellitus, protein kinase FA dysfunction, 69
necessary for intraportal glucose delivery to liver, 1247
nuclear uptake, 194
prophylactic treatment, prevention of adoptive transfer, 1273
release
effects of arachidonic acid metabolism inhibitors, 620
membrane depolarization/ Ca^{2+} influx, 438
sensitivity, high/low carbohydrate diet effects, 1278
therapy
comparison of routes of infusion, 1042

implantable pumps, 657
oral administration, insulin receptors, 451
transport, insulin sensitivity in vivo, 241
Insulin action
defects in polycystic ovary syndrome, 1257
embryo development, 318
glucose
tolerance, 750
transporter, 227, 1063
growth hormone
effect, 424
pituitary response, 17
insulin-receptor binding, 707
insulinlike growth factor binding protein release, 835
lipoprotein composition in insulin-dependent diabetes mellitus, (Suppl. 2) 107
peripheral tissue sensitivity, 241
Insulin receptor
binding
free fatty acids effects, 294
insulin effects, 707
encapsulated insulin, oral administration, 451
expression
fasting effects, 1609
retinopathy, 818
gene
mutation
detection, 408
syndromes, 1473
non-insulin-dependent diabetes mellitus
linkage analysis, 648
tyrosine kinase mutation, 521
transcription, fasting effects, 1609
immunologically distinct variants, 6
in vivo imaging, 855
mRNA coding region heterogeneity, 1293
mutations, linkage analysis, 648
pioglitazone action, 476
tissue-specific regulation of mRNA levels, 1113
tyrosine kinase activity, 1373
Insulin resistance
impaired activation of glycogen synthase, non-insulin-dependent diabetes mellitus risk factor, 598
children, racial differences, 313
glucose transporter role, 728
hyperglycemia, 274, 571
hyperinsulinemia, 274
metformin action, 354
obesity, 691
glucose metabolism, 698
pioglitazone action, 476
sodium-lithium countertransport, 610
syndrome, 1207
French Caribbean Islands, 1385
syndrome X, 715
Insulin secretion

electrical activity, 662, 1221
estimation of, C-peptide levels, 368
fasting, 508
glucose
induced, GLUT2 level, 1320
tolerance, 750
hormonal inhibition, G-protein effects, 1390
human galanin inhibition of, 82
hypoglycemia, 508
inhibition due to catecholamines, 1632
Lp(a) levels, 1341
post kidney-pancreas transplantation, 1346
Insulin-dependent diabetes mellitus
adhesion molecules, elevated levels, e adults, cognitive dysfunction, 107
aging, islet cell antibodies, 1022
albuminuria, angiotensin-converting enzyme action, 62
ambulatory blood pressure, 1035
antibodies, glutamic acid decarboxylase, 782, 1182
apoA-I, effects on reverse cholesterol transport, (Suppl. 2) 81
autoimmunity, T lymphocytes, 53
autonomic neuropathy, proliferative retinopathy risk, 430
brain edema, 627
cognitive dysfunction, hypoglycemic threshold, 392
dyslipidemia, (Suppl. 2) 111
glomerular structure, normal urinary albumin excretion, 581
glutamic acid decarboxylase
antibodies, marker, 782, 1182
isoforms, 1355
growth hormone
binding protein, 605
pituitary response, 17
heat shock proteins, 788
HLA
action, 123
susceptibility heterodimer, 378
hyperglycemia
effect on glucose metabolism, 174
insulin resistance, 571
hypoglycemia, reduced counterregulatory responses, 1335
iatrogenic hypoglycemia, 255
immunotherapy, anti-CD3 monoclonal antibodies, 385
insulin infusion, route comparisons, 1042
insulin resistance
metformin action, 354
sodium-lithium countertransport, 610
islet
cell surface antibodies, not expressed in human islet cells, transplantation, adjuvant immunotherapy, 114
lipoprotein
disorders, (Suppl. 2) 102

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
February, 123-253
March, 255-399

April, 401-556
May, 557-656
June, 657-775

July, 777-895
August, 897-1027
September, 1029-1219

October, 1221-1365
November, 1367-1501
December, 1503-1676

- glycemic control effects, 1301
 insulin treatment effects, (Suppl. 2) 107
- markers
 glutamic acid decarboxylase antibodies, 782, 1182
 pentosidine (advanced glycosylation), 1286
 mesangium, cell and matrix components, 679
 microalbuminuria, sensitivity to norepinephrine-induced vasoconstriction, 209
 nephropathy
 cardiac death risk factor, 813
 sodium-hydrogen exchange, 1239
 neuropathy, *myo*-inositol flux, 760
 nitric oxide effects, 897
 platelet aggregation, aspirin effects, 261
 prediction, islet cell antibodies, 347
 risk identification, islet cell antibodies, 183
 screening, glutamic acid antibodies, 548
 sodium retention, atrial natriuretic peptide effects, 936
 susceptibility
 DQA1 and DQB1 alleles, 914
 DR2 haplotype, 904
 identification of gene, 1029
 MHC haplotype, 1617
 T lymphocytes, glutamic acid decarboxylase, 118
- Insulinlike growth factor
 binding proteins
 kidney, 499
 molecular regulation, 835
 regulation of, 1511
 embryo development, 318
- I
 mRNA levels, 222
 obesity, 691
 renin secretion regulation, 1100
 Islet amyloid polypeptide. *See* Amylin
 Islet cell antibodies
 aging, 1022
 insulin-dependent diabetes mellitus
 prediction, 347
 risk identification, 183
 measurement of assay specificity, 1570
 surface antibodies, not expressed in human islet cells, 1624
- Islets
 allograft survival, bone marrow transplantation, 771
 cell
 destruction
 CD8 T-cells not required, 1603
 T-cell and macrophage interaction, 1380
 purification, transplantation, organ preservation, 299
 human
 glucokinase gene, 807
 pancreas, 93
 tissue content, zinc measurement, 1056
 transplantation
 adjuvant immunotherapy, 114
 growth of neonatal, 1122
 immunoisolation, 1503
 intrathymic, diabetes prevention, 1672
 reduced β -cell function, insulin resistance, 1172
 teleost fish, 1528
 Italy, insulin-dependent diabetes mellitus susceptibility, DR2 haplotype, 904
- K
 Ketones, metabolism, sulfonylurea effect, 968
- Kidney
 glucose transporter colocalization, 766
 insulin binding, 1113
 insulinlike growth factor binding proteins, 499
 pancreas transplantation, C-peptide clearance, 1346
 Kimmelstiel-Wilson nodules, distribution in glomeruli, 952
- L
 Lactate production in fat and skeletal muscle, 1547
 Laminin, changes after nonenzymatic glycation, (Suppl. 2) 49
 Lesions, segmental, Kimmelstiel-Wilson nodules, 952
- Lipid
 lowering therapy, macrovascular disease, (Suppl. 2) 111
 metabolism, implantable insulin pumps, 657
 Lipolysis, adipose tissue, prostaglandin E_2 effects, 927
- Lipoprotein
 (a) level
 in non-insulin-dependent diabetes mellitus, 1267
 insulin secretion, 1341
 abnormal composition and levels, (Suppl. 2) 12
 apoA-I, reverse cholesterol transport, (Suppl. 2) 81
 apoB-containing, identification of, (Suppl. 2) 18
 apoE, role in atherosclerosis acceleration, (Suppl. 2) 77
 glycation effects, (Suppl. 2) 67
 glycemic control effects, 1301
 high/low carbohydrate diet effects, 1278
- immune complexes, vascular complications, (Suppl. 2) 92
 insulin-dependent diabetes mellitus disorders, (Suppl. 2) 102
 insulin treatment effects, (Suppl. 2) 107
 levels
 atherosclerosis acceleration, (Suppl. 2) 86
 visceral obesity, 826
 oxidation, (Suppl. 2) 61, 74
 pregnancy, 1651
- Liver
 human insulin degradation, 539
 insulin
 binding, 1113
 intraportal glucose delivery, 1247
 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase, tolbutamide action, 334
- Lymphocytes, non-insulin-dependent diabetes mellitus, protein kinase FA dysfunction, 69
- Lymphopenia, insulin-dependent diabetes mellitus susceptibility, 1617
- M
 Macromolecules, nonenzymatic glycosylation of, (Suppl. 2) 57
 Macrovascular disease
 American Diabetes Association Council on Complications symposium, (Suppl. 2) 116
 lipid-lowering therapy, (Suppl. 2) 111
 Magnesium, effect on inositol transport, 35
 Maillard Reaction, 153, 1286, (Suppl. 2) 36
 Major histocompatibility complex
 haplotype, insulin-dependent diabetes mellitus susceptibility, 1617
 Maturity-onset diabetes of the young
 genetic mapping, 88
 glucokinase defects, 1367
 GLUT2 genes, linkage analysis, 962
 Membrane depolarization, insulin release, 438
 Mesangial cells, aldose reductase, 1165
 Mesangium, glomerular, cell and matrix components, 679
 [123]metaiodobenzylguanidine
 measurement, detection of cardiac sympathetic nervous dysfunction, 1069
 Metformin, insulin resistance, 354
 Mexican-origin population,
 non-insulin-dependent diabetes mellitus, genetic and environmental determinants, 484
- Mice
 arachidonic acid metabolism inhibitors,
 effect on insulin release, 620

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

- islet destruction, 1603
non-obese diabetic
 insulinitis, effects of
 1,25-dihydroxyvitamin D₃, 1491
intrathymic islet cell transplantation,
 1672
NOR/Lt as major histocompatibility
 complex-matched strain, 98
T-cell differences and β -cell
 destruction, 998
T-cell receptors, 308
thyroiditis incidence, 40
NOR/Lt, major histocompatibility
 complex-matched strain for
 NOD, 98
prostaglandin E₂ effect on embryo
 anomalies, 1644
transplanted islets
 pancreatic, reinnervation, 130
 teleost fish, 1528
viable yellow A^{y/a}, glucose transporter
 levels, 187
Microalbuminuria
 free radical activity, 909
 hemostatic abnormalities, 909
 mortality predictor,
 non-insulin-dependent diabetes
 mellitus, 736
 sensitivity to norepinephrine-induced
 vasoconstriction, 209
MODY. See Maturity-onset diabetes of
 the young
Monkeys
 insulin receptors, in vivo imaging, 855
 liver, human insulin degradation, 539
Monoclonal antibodies, anti-CD3,
 immunotherapy, 385
Muscle
 fat glucose transporter gene, 1436
 skeletal
 blood flow impaired in
 non-insulin-dependent diabetes
 mellitus, 1076
 exercise effect on glucose
 transporters, 920, 1091
 gene expression of GLUT4, 465
 GLUT4, 728, 1562
 glycogen synthase, hyperglycemia
 effects, 1453
 growth hormone effect, 424
 hyperglycemia, 174, 571
 lactate production, 1547
 pyruvate dehydrogenase activity, 1547
 soleus, localization of glucose
 transporter, 215
myo-Inositol
 abnormal influx in leucocytes,
 neuropathy, 760
 level, congenital malformations, 989

N
Native Americans
 apoB-containing lipoproteins, (Suppl. 2)
 18
coronary heart disease risk factors,
 (Suppl. 2) 4
Nephropathy
 ambulatory blood pressure monitoring,
 1035
 cardiac death, risk factor, 813
 coronary heart disease, (Suppl. 2) 1
 risk identification, 209
 screening, glomerular filtration rate,
 581
 sodium-hydrogen exchange, 1239
 sodium-lithium countertransport, 610
Nerve conduction
 aminoguanidine action, 47
 improvement, pancreatic-renal
 transplantation, 946
Neuropathy
 adults, psychomotor slowing, 107
 aminoguanidine action, 47
 autonomic
 heart rate spectral analysis, 633
 proliferative retinopathy risk, 430
 streptozocin-induced diabetes
 effects, 160
 axonal transport, ganglioside effects,
 866
 Maillard reaction, (Suppl. 2) 36
 myo-inositol, abnormal influx in
 leucocytes, 760
 nerve conduction, pancreatic-renal
 transplantation, 946
 niceritol effects, 587
 Niceritol, effect on neuropathy, 587
NIDDM. See Non-insulin-dependent
 diabetes mellitus
Nonenzymatic glycosylation,
 macromolecules, (Suppl. 2) 57
Nonesterified fatty acid level, suppression
 by acipimox, 1400
Non-insulin-dependent diabetes mellitus
 adenosine deaminase locus mutations,
 1640
 β -cell tropin concentrations, 1160
 Black Americans
 glucokinase gene as marker, 843
 insulin gene, 742
 carbohydrate
 high/low diet, effect on lipoproteins,
 1278
 metabolism, amylin effect, 975
 dyslipidemia, (Suppl. 2) 111
 genetic
 glucokinase gene, 1496
 mapping, 401
 mutations, familial clustering, 850
 glucose
 induced insulin secretion, GLUT2
 level, 1320
 intolerance, responsible factors,
 1540
 metabolism, medium-chain
 triglycerides, 641
 hyperglycemia, insulin resistance, 274
 hyperinsulinemia, insulin resistance,
 274
incidence
 coronary heart disease, 1141
 obesity, 235
 inheritance, genetics, 416
 insulin receptor gene
 analysis, 648
 tyrosine kinase mutation, 521
 insulin resistance, syndrome X, 715
 insulin therapy, implantable pumps,
 657
ketone metabolism, sulfonylurea effect,
 968
linkage analysis, GLUT1 and GLUT2,
 1660
Lp(a) concentrations, 1267
lymphocytes, protein kinase FA
 dysfunction, 69
marker, glucokinase gene, Black
 Americans, 843
maturity-onset diabetes of the young
 genetic linkage analysis, 962
 glucokinase defects, 1367
Mexican-origin populations, genetic
 determinants, 484
microalbuminuria, free radical activity,
 909
mortality predictor, microalbuminuria,
 736
Native Americans, apoB-containing
 lipoproteins, (Suppl. 2) 18
obesity
 acipimox suppression of
 nonesterified fatty acid levels,
 1400
 glucose metabolism, 698
 skeletal muscle blood flow, 1076
 offspring, metabolic profile, 1575
 Pima Indians, coronary heart disease,
 1141
 prevalence, racial differences, 313
 retinopathy, North American Indians,
 359
 risk factor
 coronary heart disease, (Suppl. 2) 1
 Native Americans, (Suppl. 2) 4
 impaired glycogen synthase, 596
 skeletal muscle, gene expression of
 GLUT4, 465
 vasculopathy, proinsulin effects, 890
Nitric oxide, effects on insulin-dependent
 diabetes mellitus, 897
Nitrogen wasting, decreased by glucagon
 immunoneutralization, 12
Norepinephrine
 effect on fast response, 30
 -induced vasoconstriction, sensitivity to,
 209
North American Indians, retinopathy,
 incidence, 359

O
Obesity
 amylin expression, 685

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
February, 123-253
March, 255-399

April, 401-556
May, 557-656
June, 657-775

July, 777-895
August, 897-1027
September, 1029-1219

October, 1221-1365
November, 1367-1501
December, 1503-1676

- duration, incidence of
non-insulin-dependent diabetes
mellitus, 235
- glucose metabolism, body fat
distribution, 1151
- glycerol production and utilization, 444
- insulin
changes in sensitivity, 1257
gene expression, 685
receptor binding, free fatty acids
effects, 294
resistance, 691
insulinlike growth factor I, 691
non-insulin-dependent diabetes
mellitus
acipimox suppression of
nonesterified fatty acid levels,
1400
glucose metabolism, 698
skeletal muscle blood flow, 1076
skeletal muscle, gene expression of
GLUT4, 465
visceral, glucose tolerance, 826
- Oleate, effects on glucose transporters,
1063
- Oxygen cross-linking effects, glucose
modification of collagen, (Suppl.
2) 42
- P**
- Pancreas
artificial, diffusion-based hybrid, 886
human, islet cellular perfusion, 93
kidney transplantation, C-peptide
clearance, 1346
- Pentosidine
Maillard reaction marker, 1286
quantitation in diabetes and uremia,
153
- Perineurial cells, target for GLUT1 protein
decrease, 1587
- Pertussis toxin-sensitive substrates in
HIT cell, 1390
- Phosphoribosyl pyrophosphate formation
in adrenal gland, 1429
- Physical activity, non-insulin-dependent
diabetes mellitus determinant,
484
- Pima Indians
non-insulin-dependent diabetes
mellitus
coronary heart disease,
prevalence/incidence, 1141
obesity, incidence, 235
- Pituitary, response to growth hormone,
17
- Platelet
abnormalities, (Suppl. 2) 26
activation, (Suppl. 2) 32
aggregation, insulin-dependent
diabetes mellitus, aspirin effect,
261
- Polycystic ovary syndrome, defects in
insulin action, 1257
- PolyI:C
diabetes development in rats, 515
effect on diabetes development, 1016
- Polymerase chain reaction, T-cell
receptors, 308
- Polyol
pathway, activity in and sorbitol
accumulation, 1050
theory, hypomagnesemia, model for
complications development, 35
- Pregnancy, plasma lipoproteins, 1651
- Prevalence, non-insulin-dependent
diabetes mellitus, racial
differences, 313
- Proinsulin
measurement in human serum, 1084
non-insulin-dependent diabetes
mellitus, vasculopathy, 890
- Prostacyclin
adipose tissue, effects on lipolysis, 927
effect on glomerular filtration rate, 533
effect on renal plasma flow, 533
- Prostaglandin E₂
adipose tissue, effects on lipolysis, 927
embryo anomalies, effect on, 1644
- Protein
glycosylation, vitamin C effect, 167
kinase C activation, effect on vascular
smooth muscle cells, 1464
kinase FA, dysfunction in
non-insulin-dependent diabetes
mellitus, 69
- Pulmonary artery, zero stress state, 136
- Pyruvate
dehydrogenase activity in fat and
skeletal muscle, 1547
oxidation, cellular, gene transcription,
339
- R**
- Rats
BB
forebrain ischemia, 1328
polyI:C effect on diabetes
development, 1016
prophylactic insulin, prevention of
adoptive transfer, 1273
susceptibility, 1617
tetrandrine effects, 616
- BB/Wor
neonatal islet transplants growth,
1122
polyI:C, 515
staphylococcal enterotoxins, 527
T lymphocytes, glutamic acid
decarboxylase, 118
- Fischer, glomerular function, 1106
liver, human insulin degradation, 539
Long-Evans, OLETF strain, 1422
Munich-Wistar, renal functional
reserve, 267
- norepinephrine effect on fast response,
30
- obese *fa/fa*, corticotropin-releasing
factor, 493
- Otsuka Long-Evans Tokushima Fatty
(OLETF) strain, 1422
- Sprague-Dawley
basic fibroblast growth factor, 222
exercise effects on glucose
transporters, 920, 1091
free fatty acids effects, 294
hyperglycemia effects on skeletal
muscle glycogen synthase, 1453
gangliosides effects on axonal
transport, 866
insulinlike growth factor binding
proteins, 499, 835
insulin resistance, glucose
transporter role, 728
insulin-receptor binding, 707
mRNA heterogeneity, 1293
renin secretion regulation, 1100
- Wistar
atrial natriuretic peptide, 533
brain D1 dopamine receptor, 1119
Ca²⁺ influx, 438
fasting effects, 508
glucagon immunoneutralization, 12
glucose transporter isoform
expression, 76
hypoglycemia effects, 508
hypothyroidism, 147
liver glucose transporter, 22
localization of glucose transporter,
215
pioglitazone action, 476
- Wistar Kyoto, glucose tolerance in
hypertension, 872
- Zucker *fa/fa*, glucose transporter levels,
187
- Zucker, obese
insulin and amylin expression, 685
insulinlike growth factor I, 691
insulin resistance, 691
See also Streptozocin-induced
diabetes
- Renal
functional reserve, 267
plasma flow
atrial natriuretic peptide effects, 533
prostacyclin effects, 533
- Retinopathy
incidence, North American Indians, 359
insulin receptor expression, 818
proliferative, genetic markers, 879
resistance to endothelin-1, 1533
risk factors, autonomic neuropathy, 430
- Risk factors
cardiac death, nephropathy, 813
coronary heart disease, (Suppl. 2) 1
hypoglycemia, aging, 671
retinopathy, autonomic neuropathy,
430
- RNA heteroduplex mapping, 1293

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
February, 123-253
March, 255-399

April, 401-556
May, 557-656
June, 657-775

July, 777-895
August, 897-1027
September, 1029-1219

October, 1221-1365
November, 1367-1501
December, 1503-1676

S

- Schwann cells, 1587
- Sodium
 - hydrogen exchange, insulin-dependent diabetes mellitus, 1239
 - lithium countertransport, insulin resistance, 610
 - retention, insulin-dependent diabetes mellitus, atrial natriuretic peptide effects, 936
- Sorbitol accumulation, activity in polyol pathway, 1050
- Staphylococcal enterotoxins, activation of diabetes-inducing T cells, 527
- Streptozocin-induced diabetes
 - mice, immunotoxins, 457
 - rats
 - adrenal growth, 1429
 - aminoguanidine effects on nerves, 47
 - amylin secretion, 723
 - cerebral taurine transport, 1130
 - chylomicron metabolism, 325
 - fasting effects on insulin receptor expression/gene transcription, 1609
 - glomerular dynamics, 286
 - glucose
 - induced insulin secretion, GLUT2 level, 1320
 - sensitivity, 861
 - hypothyroidism, 147
 - insulinlike growth factor binding protein regulation, 1511
 - insulin receptor mRNA levels, 1113
 - lactate production, 1587
 - niceritol effects, 587
 - norepinephrine effects on fast response, 30
 - parasympathetic nervous system, 160
 - phosphoribosyl pyrophosphate formation, 1429
 - pyruvate dehydrogenase activity, 1547
 - renal functional reserve, 267
 - retinopathy, 818
 - zero stress state, 136

- zinc ion effects, 982
- Sulfonylurea, effect on ketone metabolism, 968
- Synaptosomes, hyperglycemia, 1130
- Syndrome X, 715

T

- T cells
 - CD4⁺/CD8⁺, difference in β -cell destruction, 998
 - CD8 cells not required for islet destruction, 1603
 - interaction with macrophages, 1380
 - receptors, polymerase chain reaction, 308
- T lymphocytes
 - glutamic acid decarboxylase, 118
 - pancreas allograft, isletitis, 53
 - Taurine transport, 1130
 - Teleost fish islet transplantation, 1528
 - Tetrandrine, prevention of spontaneous diabetes development in rats, 616
 - Thyrogastic antibodies, aging, 1022
 - Thyroiditis, incidence, non-obese diabetic mice, 40
 - Thyroxine (T₄), 147
 - Tissue plasminogen activator expression, endothelial cells, 1009
 - Tolbutamide, inhibition of phosphorylation of bifunctional enzyme, 334
 - Transplantation
 - bone marrow, islet allograft survival, 771
 - islets
 - adjuvant immunotherapy, 114
 - immunoisolation, 1503
 - intrathymic, diabetes prevention, 1672
 - kidney-pancreas, C-peptide clearance, 1346
 - mice pancreatic islets, reinnervation, 130
 - neonatal islet, growth, 1122
 - organ preservation, islet cell purification, 299

- pancreatic-renal, improvement in nerve conduction, 946
- rat pancreatic islets, 1555
- Triglycerides, medium-chain, effect on glucose metabolism, 641
- Triiodothyronine (T₃), 147
- Tyrosine kinase
 - activity
 - free fatty acids effects, 294
 - insulin receptor, 1373
 - mutation, non-insulin-dependent diabetes mellitus, 521

U

- Urea synthesis, normalized by glucagon immunoneutralization, 12
- Uremia, pentosidine levels, 153
- Urinary albumin excretion, nephropathy screening, 581

V

- Vascular
 - complications, lipoprotein-immune complexes, (Suppl. 2) 92
 - dysfunction, aminoguanidine effects, 552
 - smooth muscle cells, protein kinase C activation, 1464
- Vitamin C, protein glycosylation, 167

W

- Women, hyperglycemia and cardiovascular disease, 202

Z

- Zero stress state, pulmonary artery, 136
- Zinc
 - ion, insulinlike effects on adipocytes, 982
 - measurement as indicator of islet tissue content, 1056

Author Index

A

Abbassi, V., 515
Ader, M., 241, 750
Adezzati, L., 1009
Adkins-Marshall, B.A., 1308
Agius, L., 1400
Ahmed, S., 1429
Ailhaud, G., (Suppl. 2) 81
Aizawa, T., 438
Akanuma, Y., (Suppl. 2) 126
Akots, G., 88
Alam, T., 508
Alaupovic, P., (Suppl. 2) 18
Alberti, K.G.M.M., 1400
Alcolado, J.C., 1640
Al-Daccak, R., 378
Alexander, D., 1511
Alford, F.P., 1446
Almdal, T.P., 12
Alper, C.A., 347, 788
Altan, V.M., (Suppl. 2) 128
Alyassin, A.M., 1151
Andalibi, A., (Suppl. 2) 74
Andersen, P., 174
Anderson, K.M., 202
Andersson, A., 130
Andres, R., (Suppl. 2) 122
Antonipillai, I., 1100
Aoki, M., 334
Appel, M.C., 308
Asano, T., 22
Atef, N., 685
Avogaro, A., 968
Awdeh, Z.L., 347, 788
Axelrod, L., 927
Ayrancioglu, K., (Suppl. 2) 128
Azhar, S., 1547

B

Baas, E., 855
Baba, M., 47
Bacci, B., 866
Bach, L.A., 499
Bacher, J.D., 855
Bagdade, J.D., (Suppl. 2) 107
Bain, S.C., 1029
Balzani, I., 633
Banga, J.D., (Suppl. 2) 127
Bannon, M., (Suppl. 2) 122
Bao, W., 313
Barbetti, F., 408
Barbosa, J.J., 53
Bard, J.-M., (Suppl. 2) 18
Barker, C.F., 771

Barnett, A.H., 914
Barnett, D.W., 682, 1221
Baron, A., 465, 1076
Baroni, M.G., 1640
Barrett, E.J., 424
Barrow, B., 1496
Barton, R.W., (Suppl. 2) 125
Barzilai, J., 430
Battezzati, A., 1632
Baumann, G., 605
Baxter, M.A., 35
Baynes, J.W., (Suppl. 2) 42
Beck, F., 318
Becker, G.W., 539
Beck-Nielsen, H., 174
Beguinot, F., 521
Beisswenger, P.J., (Suppl. 2) 121
Bell, G.I., 401, 962, 1436
Bell, J., (Suppl. 2) 124
Bellanti, J.A., 515, 1016
Bellavere, F., 633
Beloff-Chain, A., 1160
Benigni, A., 533
Benjamin, A., 818
Bennett, P.H., 235, 1141
Berenson, G.S., 313
Bergman, R.N., 241, 750
Berliner, J.A., (Suppl. 2) 74
Berman, J.N., 641
Bernard, N.F., 40
Bertrams, J., 1668
Bertrand, S., 1273
Best, J.D., 1446, (Suppl. 2) 125
Bhushan, R., 17
Bianchi, E., 1632
Billan, P.J., 227
Bilous, R.W., 679
Björntorp, P., 294
Blackman, J.D., 392, 1346
Blair, O., 515
Blantz, R.C., 267
Blazar, B.R., 457
Bluestone, J.A., 385
Boden, G., 1063
Bodmer, C.W., 209
Boel, E., 1355
Boeri, D., 1009
Bomford, J., 760
Bonadonna, R.C., 1151
Bonner-Weir, S., 347, 1320
Bonora, E., 1151
Bonora, E., 408
Borboni, P., 6
Borland, K.M., 886
Bornemann, A., 215
Bottazzo, G.F., 782
Bouchard, C., 826

Bougnères, P.F., 444
Bouillon, R., 1491
Bowden, D.W., 88
Bown, E., 1496
Bowsher, R.R., 1084
Bracy, D., 1229
Bradley, B.J., 1603
Brass, E.P., 641
Bray, G.A., 750
Brechtel, G., 1076
Brief, S., 457
Brocco, E., 936
Brown, G., 35
Brown, T.J., 782
Brownlee, M., 26, (Suppl. 2) 57
Buchanan, T.A., 872
Bue, J., 187
Bunce, C.M., 35
Bunting, C.E., (Suppl. 2) 125
Burdett, E., 1562
Burke, V., 261
Buse, J.B., 1436
Buzzetti, R., 904
Bylander, J.E., 1050

C

Cagliero, E., 1009
Cama, A., 408
Campese, V.M., 872
Capaldo, B., 521
Caprio, S., 17
Carenza, P., 633
Carraro, A., 936
Carraro, M., 633
Carretta, M., 886
Carroll, S.F., 457
Carson, R.E., 855
Cassidy, D., 782
Castro, G., (Suppl. 2) 81
Catalano, C., 1400
Cavan, D.A., 914
Chambers, J., 610
Chang, K., 552
Chang, K.S.K., 160
Channing, M.A., 855
Charles, M.A., 1141
Charonis, A.S., (Suppl. 2) 49
Chatzipanteli, K., 927
Chen, A.Y., 641
Chen, C., 1320
Chen, L., 508
Chen, Q.-Y., 548
Cherrington, A.D., 1247, 1308
Chick, W.L., 886, 1503

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
February, 123-253
March, 255-399

April, 401-556
May, 557-656
June, 657-775

July, 777-895
August, 897-1027
September, 1029-1219

October, 1221-1365
November, 1367-1501
December, 1503-1676

Chisolm, G.M., (Suppl. 2) 61
 Chiu, K.C., 843, 1367
 Chonko, A.M., 62, 1035
 Christensen, C.K., 812
 Christensen, P.D., 812
 Christianson, S.W., 1672
 Christie, M.R., 782
 Christopher, M.J., 1446
 Christopher, P., 1496
 Ciaraldi, T.P., 975
 Cingolani, H.E., 30
 Cipollina, M.R., 936
 Clark, P.M.S., (Suppl. 2) 124
 Clutter, W.E., 671
 Cobelli, C., 633
 Cockram, C.S., 914
 Cocozza, S., 521
 Colle, E., 1617
 Collier, A., 909
 Condorelli, G., 521
 Condorelli, L., 6
 Connolly, C.C., 1308
 Connors, M.A., 989
 Cook, J.T.E., 1496
 Cookson, W.O.C.M., 1496
 Cooper, H.N., 1122
 Cooper, M., (Suppl. 2) 123
 Corbett, J.A., 552, 897
 Costanzi, S., 904
 Cowan, L.D., (Suppl. 2) 4
 Cox, A.J., 499
 Cox, N.J., 401
 Cram, D.S., 1182
 Cramer, S.C., 766
 Cremel, G., 451
 Creswell, K., 515
 Crook, D., 1341
 Cruickshanks, K.J., 879
 Cryer, P.E., 255, 671
 Curphey, T.J., (Suppl. 2) 121

D

Dai, F., 1328
 Damgé, C., 451
 Daneman, D., 227
 Daniels, B.S., 1415
 Davenport, M., 1160
 Davie, S.J., 167
 Davis, M.R., 1335
 Deaizpurua, H.J., 1182
 DeFronzo, R.A., 1151, 1575
 Degos, L., 378
 De Grazia, U., 904
 de Groot, P.G., (Suppl. 2) 127
 Deguchi, K., 592
 de la Rubia, G., 1533
 Del Prato, S., 968, 1151
 Deluca, F., 1063
 De Masi, G., 633
 De Nicola, L., 267
 De Paepe, M., 1273
 De Pirro, R., 6

De Riva, C., 533
 Desbuquois, B., 1609
 Deschamps, I., 378
 Després, J.-P., 826
 De Vries, R.R.P., 1380
 The Diabetes Incidence Study in Sweden
 Group, 1022
 Diaz, J.-L., 118
 Di Carlo, V., 1632
 Dobrjansky, A., 1257
 Dominiczak, M.H., (Suppl. 2) 124
 Donaldson, D.L., 1035
 Douen, A., 1562
 Douglas, A.J., 261
 Drews, G., 620
 Drouin, P., (Suppl. 2) 81
 Duchateau, P., (Suppl. 2) 81
 Duckworth, W.C., 657
 Dudley, A.L., 1293
 Dunaif, A., 1257
 Duner, E., 968
 Dunn, B.B., 855
 Dunn, F.L., (Suppl. 2) 102, 107, 121
 Durr, J.A., 627
 Dyrberg, T., 1355

E

Earle, K., 1239
 Eastman, R.C., 855
 Ebihara, I., 1520
 Eckel, R.H., 641
 Edelman, S.V., 1076
 Edelstein, D., 26
 Eduoard, P., 1617
 Egawa, K., 476
 Eisenbarth, G.S., 347, 788
 El Gammal, T., 627
 Elbein, S.C., 416, 648, 1660
 Ellerman, K.E., 527
 Elliott, M.E., 227
 Ellis, E.N., 1106
 Eriksson, J., 707
 Eriksson, J.G., 354
 Erlich, H., 347
 Ertug, F., 40
 Eschwege, E., 1385
 Esmeraldo, R., 1056
 Estworthy, S., (Suppl. 2) 74
 Evans, J.C., 202
 Everhart, J.E., 235
 Ewel, C.H., 515, 1016
 Exell, L., 318
 Ezaki, O., 920

F

Fabsitz, R.R., (Suppl. 2) 4
 Fajans, S.S., 88, 401
 Falke, L.C., 662
 Farrace, S., 1453
 Feingold, K.R., 325, (Suppl. 2) 97

Ferrannini, E., 1575
 Ferrara, A., 521
 Ferrari, G., 1632
 Fievet, C., (Suppl. 2) 81
 Figliomeni, B., 866
 Finegold, D.N., 107
 Finegood, D.T., 1172
 Fioretto, P., 936
 Fiori, M.G., 866
 Fitzgerald, A.P., 736
 Flath, M.C., 1050
 Fleg, J., (Suppl. 2) 122
 Fletcher, J.A., 914
 Flier, J.S., 1207
 Fogarolo, F., 866
 Fogarty, J., 153, 1286
 Fogelman, A.M., (Suppl. 2) 74
 Fontbonne, A., 1385
 Frank, B.H., 1084
 Frankel, W.N., 98
 Fruchart, J.-C., (Suppl. 2) 81
 Fryburg, D.A., 424
 Fu, M.-X., (Suppl. 2) 42
 Fujihara, C.K., 286
 Fujisawa, K., (Suppl. 2) 128
 Fukasawa, H., 587
 Fuks, A., 1617
 Fukui, M., 1520
 Fukumoto, H., 76
 Fukushima, M., 1540
 Fulcher, G.R., 1400
 Fung, Y.-C., 136
 Fushimi, N., (Suppl. 2) 126
 Futterweit, S., 1130

G

Gabanelli, M., 533
 Gabbai, F.B., 267
 Galluzzo, A., 788
 Galton, D.J., 1640
 Garg, A., 1278, (Suppl. 2) 111
 Garrino, M.-G., 620
 Garvey, W.T., 274, 465
 Gatta, A., 936
 Gefel, D., 982
 Gejman, P.V., 408
 Gelato, M.C., 1511
 Gelfand, R.A., 424
 Georgopoulos, A., (Suppl. 2) 126
 Gerling, I.C., 1672
 Gerow, K.E., 424
 Ghiatas, A.A., 1151
 Gianani, R., 347
 Gibbs, E.M., 1360
 Gillis, K.D., 662, 1221
 Giorato, C., 936
 Girard, J., 685
 Gisinger, C., (Suppl. 2) 92
 Glahn, U., (Suppl. 2) 125
 Gnudi, L., 968
 Goddard, I.F., 1341
 Goldberg, M., 975

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

Goldfine, I.D., 6
 Goldman, A.S., 1644
 Goldstein, B.J., 1293
 Goldstein, S., 835
 Golichowski, A.M., 465
 Gomis, R., 1624
 Goncharov, V.G., 1042
 Gonzalez, C., 484
 Goodyear, L.J., 1091
 Gosling, R.G., (Suppl. 2) 122
 Goto, M.P., 1644
 Goto, Y., 339
 Gould, B.J., 167
 Gould, G.W., 1360
 Grady, E.F., 1113
 Grafton, G., 35
 Grandhee, S., (Suppl. 2) 36
 Gravius, T.C., 88
 Gray, D.W.R., 1056
 Green, G., 1257
 Greenawalt, K., 691
 Greenbaum, A.L., 1429
 Greenbaum, C.J., 1570
 Gress, R.E., 385
 Gries, F.A., (Suppl. 2) 127
 Griffin, C.A., 1113
 Groop, L.C., 354, 598
 Groth, C.-G., 946
 Gruber, M.K., 1267
 Grubin, C.E., 1355
 Grundy, S.M., 1278
 Grunfeld, C., 1113, (Suppl. 2) 97
 Gulli, G., 1151, 1575
 Guttmann, R.D., 1617
 Gwynne, J.T., (Suppl. 2) 116
 Gyda, M., 1063

H

Ha, T.-L., 68
 Haber, R.S., 728
 Haffner, S.M., 484, 715, 1267, 1575
 Hagopian, W.A., 1355
 Hales, C.N., (Suppl. 2) 124
 Hammonds, P., 118
 Hancock, J.A., 465
 Haneda, M., 1165
 Hanson, A.S., 641
 Haraguchi, Y., (Suppl. 2) 128
 Harano, Y., (Suppl. 2) 126
 Haring, H.-U., 6
 Härkönen, M., 598
 Harrison, L.C., 1182
 Hasan, K.S., 552
 Haskins, K., 1603
 Hasstedt, S.J., 416
 Hattersley, A.T., 962, 1496
 Hauser, E.B., 1415
 Hawkins, B.R., 914
 Hazuda, H.P., 484, 715
 Heath, W.F., 187
 Hegre, O.D., 1122
 Heindorf, H., 12

Henquin, J.-C., 620
 Henry, R.R., 657
 Herington, A.C., 499
 Herold, K.C., 385
 Herrera, E., 1651
 Herron, K.G., 62
 Hidaka, H., (Suppl. 2) 128
 Higuchi, M., 920
 Hilton, C., 313
 Hirai, S., 1373
 Hirashima, T., 1422
 Hirata, Y., (Suppl. 2) 126
 Hirayama, B.A., 766
 Hirochika, R., 956
 Hirsch, R., 385
 Hirshman, M.F., 1091
 Hisatomi, A., 723
 Hoffman, M.D., 1660
 Hoffman, W.H., 627
 Hollands, J., 782
 Hollenbeck, C.B., 1547
 Holst, J.J., 12
 Homberg, M., (Suppl. 2) 127
 Horie, M., 861
 Hors, J., 378
 Horton, E.S., 1091
 Horton, R., 1100
 Hother-Nielsen, O., 174
 Hotta, N., 587
 How, T.V., 209
 Howard, B.V., (Suppl. 2) 4
 Howie, A.J., 952
 Huang, B., 318
 Hubert, P., 451
 Hunt, S.C., 416
 Hwang, H.-S., 68

I

Iannicola, C., 904
 Ibrahim, S.A., (Suppl. 2) 36
 Ideus, P., 1035
 Ido, Y., 552
 Ikizler, C., (Suppl. 2) 128
 Imagawa, K.-I., 592
 Imura, H., 76, 592, 861, 1540, 1555
 Inagaki, N., 76, 592
 Inoguchi, T., 1533
 Inoue, G., 592
 Inoue, H., 334
 Inoue, K., 723
 Irwin, K.C., (Suppl. 2) 61
 Ishida, H., 861, 1555
 Ishihara, H., 22
 Itakura, H., 920
 Itakura, M., 956
 Itoh, H., (Suppl. 2) 126
 Iwanishi, M., 476

J

Jackson, G., 736
 Jackson, R.A., 347

Jacob, R.J., 691
 Jacobs, K.H., 914
 Jacobson, K.A., 855
 Jain, S., (Suppl. 2) 124
 Janssen, R., 742
 Jansson, L., 130
 Janus, E.D., (Suppl. 2) 125
 Jarett, L., 194
 Jarrett, R.J., (Suppl. 2) 1
 Jaspán, J.B., 1308, 1346
 Jean, Y.-J., 68
 Jeanrenaud, B., 493
 Jenkins, A.J., (Suppl. 2) 125
 Jenkins, D., 914
 Jerums, G., 499, (Suppl. 2) 123
 Jindal, R.M., 1056
 Jones, E., 855
 Jones, I.R., 1547
 Jones, S.L., 610
 Jost-Vu, E., 1100

K

Kafonek, S.D., (Suppl. 2) 126
 Kahn, B.B., 1360
 Kajiwara, N., 1165
 Kaku, K., 334
 Kakuta, H., 587
 Kalinyak, J.E., 1113
 Kallan, A.A., 1380
 Kamijo, M., 47
 Kanatsuka, A., 1409
 Kaneko, T., 334
 Karam, J.H., 1436
 Karasu, Ç., (Suppl. 2) 128
 Karlén, A.E., 82, 1355
 Karlsson, F.A., 1022
 Karpen, C.W., 222
 Katagiri, H., 22
 Kato, S., 1555
 Kawabata, T., (Suppl. 2) 128
 Kawakami, Y., 956
 Kawamura, H., 1540
 Kawanaka, K., 920
 Kawano, K., 1422
 Keen, H., 736
 Kelley, D.E., 698
 Kelly, P., 1229
 Kemmer, K.A., 1122
 Khalil, I., 378
 Khambatta, S.S., 539
 Kikkawa, R., 1165
 Kilcoyne, R.F., 1151
 Kilpatrick, E.S., (Suppl. 2) 124
 Kim, J., (Suppl. 2) 74
 King, G.L., 1533
 Kirk, K.L., 855
 Kishimoto, T.K., 1668
 Klein, R., 879, 1301
 Klip, A., 227, 1562
 Knecht, K.J., (Suppl. 2) 42
 Knowler, W.C., 235, 1141
 Knowles, W.J., 548
 Kobayashi, M., 476

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

Koh, N., 587
 Koide, H., 1520
 Koivisto, V.A., 571
 Kojima, H., (Suppl. 2) 128
 Kolb, H., 1668
 Komatsu, M., 438
 Komori, H., 587
 Koppikar, G.D., (Suppl. 2) 124
 Koranyi, L.I., 685, 807
 Korbitt, G.S., 299
 Korsgren, O., 130
 Koschinsky, T., (Suppl. 2) 125
 Kovalev, P.A., 1042
 Kowalyk, S., 82
 Kowluru, A., (Suppl. 2) 127
 Kowluru, R.A., (Suppl. 2) 127
 Kozlowski, P., 1328
 Kraemer, F.B., (Suppl. 2) 77
 Krolewski, A.S., 430, 850
 Ksiazek, J., (Suppl. 2) 125
 Kuikka, J., 1069
 Kunjara, S., 1429
 Kurose, T., 861, 1555
 Kurosumi, M., 1422
 Kwaan, H.C., (Suppl. 2) 32

L

Laakso, M., 1076
 Lacković, Z., 1119
 Lacy, D.B., 1229
 Lafferty, K.J., 1603
 Lai, Y.-G., 68
 Lammiman, M.J., 318
 Lampeter, E.R., 1668
 Lancaster, J.L., 1151
 Lancaster, J.R., Jr., 552
 Landin-Olsson, M., 1022
 Lane, P.H., 581
 Langfield, D., 879
 Lansimies, E., 1069
 Lanza, R.P., 886, 1503
 Lapolla, A., 1286
 La Rocca, E., 1632
 La Rosa, F.G., 1603
 Lasunción, M.A., 1651
 Laureys, J., 1491
 Lauro, R., 6
 Lay, T.P., 1436
 Le, N.-A., (Suppl. 2) 4
 Leach, J.P., 909
 Leahy, J.L., 1320
 Lee, A., 750
 Lee, E.T., 359, (Suppl. 2) 4
 Lee, V.S., 359
 Lee, W.K., (Suppl. 2) 124
 Leffert, J.D., 508
 Lehmann, E.D., (Suppl. 2) 122
 Leiter, E.H., 98, 1672
 Lentz, D.P., 616
 Lepage, V., 378
 Lemmark, Å., 1022, 1355, 1570
 Leslie, R.D.G., 782

Lesniak, M.A., 855
 Le Stunff, C., 444
 Levy, J.C., 1160
 Lewis, G.F., 392
 Lewis, J.T., 1172
 Li, L.K., 1239
 Liang, Y., 792
 Liao, F., (Suppl. 2) 74
 Licholai, T., 1257
 Lieberman, I., 616
 Liebow, I.M., 1141
 Like, A.A., 527
 Lin, J.-L., 22
 Lindop, G.B.M., (Suppl. 2) 124
 Liu, Q.Z., 1141
 Liu, S.Q., 136
 Lo, S.S.S., 782
 Lo, Y.-M.D., 962
 Lodge, P., 886
 Lönnroth, P., 294, 707
 Lopes de Faria, J.B., 610
 Lopes-Virella, M.F., 1301, (Suppl. 2) 86, 92
 Lorenzi, M., 1009
 Louard, R.J., 424
 Lowe, G.D.O., 909
 Lowe, W.L., Jr., 222
 Lu, M., 359
 Lucas, A., 1624
 Lund, D.D., 160
 Lupien, P.J., 826
 Lusi, A.J., (Suppl. 2) 74
 Luskey, K.L., 508
 Luzi, L., 1632
 Lyons, T.J., (Suppl. 2) 67

M

MacDonald, F., 610
 MacDougall, M.L., 62
 Mackay, I.R., 548
 Maclaren, N.K., 879, 1570
 Madsen, O.D., 1355
 Maeda, S., 1165
 Maezawa, H., (Suppl. 2) 128
 Magnuson, M.A., 792
 Maianu, L., 274, 465
 Maiello, M., 1009
 Mainolfi, E.A., 1668
 Maki, T., 886
 Makino, H., 1409
 Mandarino, L.J., 698
 Manetta, J., 187
 Mantero, F., 936
 Mäntysaari, M., 1069
 Maran, A., 968
 Marette, A., 1562
 Margolese, H., 40
 Mariash, C.N., 339
 Marini, M.A., 6
 Marker, J.C., 671
 Marsh, K., 1511
 Martin, B.C., 430, 850

Martin, I.K., 1446
 Martin, S., 1668
 Mascardo, R.N., (Suppl. 2) 125
 Masnyk, M., 539
 Mathewes, S.L., 82
 Mathieu, C., 1491
 Matschinsky, F.M., 792
 Matsutani, A., 334, 1660
 Matsuzawa, Y., (Suppl. 2) 126
 Mattock, M.B., 610, 736
 Mauer, S.M., 581, 679
 Mayor, P., 274
 McCall, A.L., 557
 McCulloch, R.K., 261
 McDaniel, M.L., 552, 897
 McKnight, G.L., 82
 Mclean, P., 1429
 McMillan, D.E., (Suppl. 2) 116, 128
 Melican, D.T., 308
 Mellman, M., 1335
 Mendelsohn, F.A.O., 499
 Mercado, M., 605
 Messent, J., 1239
 Mestrez, F., 368
 Metzger, B.E., 989
 Michel, C., 451
 Michelsen, B.K., 1355
 Miele, C., 521
 Mijovic, C.H., 914
 Misler, S., 662, 1221
 Mitchell, B.D., 484, 715
 Miyabo, S., (Suppl. 2) 126
 Miyata, S., (Suppl. 2) 36
 Miyazaki, J.-I., 1409
 Mogensen, C.E., 812
 Moghetti, P., 408
 Mohr, T., 1229
 Mogan, M., 698
 Molenaar, J.L., 1570
 Mølgaard, H., 812
 Molitch, M.E., 605
 Monaco, A.P., 886
 Mondon, C.E., 1547
 Monnier, V.M., 153, 1286, (Suppl. 2) 36
 Montag, A.G., 385
 Montelongo, A., 1651
 Montemurro, A., 6
 Monticelli, A., 521
 Moore, L.L., (Suppl. 2) 121
 Moore, M.C., 1247
 Moore, W.V., 62, 1035
 Moorjani, S., 826
 Morales, P.A., 715, 1267
 Mori, S., 1422
 Mori, T.A., 261
 Morocutti, A., 936
 Morohoshi, M., (Suppl. 2) 128
 Morris, P.J., 1056
 Morrish, N.J., 736
 Morton, J.L., 1160
 Moss, S.E., 879
 Muggeo, M., 408
 Muller, D., (Suppl. 2) 122
 Muller, T.E., 886
 Muona, P., 1587

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

Murakami, K., (Suppl. 2) 126
 Murer, E., 1063
 Murphy, L.J., 835
 Mustonen, J., 1069

N

Nadeau, A., 826
 Nagai, K., 47
 Nagaraj, R.H., (Suppl. 2) 36
 Nagata, I., 1540
 Nagata, M., 998
 Nagataki, S., 1570
 Nagi, D.K., (Suppl. 2) 124
 Najafi, H., 792
 Naji, A., 771
 Nakai, Y., 1540
 Nakajo, Y., (Suppl. 2) 128
 Nakamura, T., x, (Suppl. 2) 128
 Nakatsuka, H., 920
 Nakauchi, H., 956
 Nakhleh, R.E., 53
 Nastasi, K., 313
 Nathan, D.M., 202
 Natori, T., 1422
 Navab, M., (Suppl. 2) 74
 Nawata, H., 723
 Neal, A.R., 1390
 Neal, D.W., 1247, 1308
 Needham, E.W.A., 1640
 Nelson, R.G., 1141
 Nerup, J., 962
 Newbold, K.M., 952
 Newsome, J., 515
 Ng, L.L., 760
 Nievelstein, P.F.E.M., (Suppl. 2) 127
 Nishimura, C., 1165
 Nistico, L., 904
 Nordt, T.K., 890
 Nosadini, R., 936, 968

O

Odetti, P., 153, 1009, 1286, (Suppl. 2) 36
 Odom, R., 975
 Odorico, J.S., 771
 Ogawa, A., 508
 O'Hara, P.J., 82
 Ohmoto, Y., 592
 Ohsawa, H., 1409
 Oka, Y., 22
 Okada, N., 438
 Okada, Y., 861
 Okamoto, Y., 76, 592, 861, 1555
 Olansky, L., 742
 Oliver, F.J., 1533
 Oliver, M.F., 1341
 Olson, A.L., 1436
 O'Neil, J.J., 308
 Opik, A.J., (Suppl. 2) 4
 Opocher, G., 936
 Orchard, T.J., 107

Orimo, H., (Suppl. 2) 126
 Osborne, H.E., 187

P

Padilha, R.M., 286
 Pagliassotti, M.J., 1247
 Palinski, W., (Suppl. 2) 125
 Pallardo, L.F., 1651
 Palmer, J.P., 1570
 Palmer-Crocker, R., 183
 Pan, X.-M., 325
 Panozzo, C., 866
 Pao, C.-I., 835
 Papoz, L., 1385
 Pardini, B.J., 160
 Partridge, W.M., 766
 Parhami, F., (Suppl. 2) 74
 Parihar, A., 385
 Patel, P., 962, 1496
 Paterson, J.R., 909
 Patrick, A.W., 209
 Peeling, J., 1328
 Peltonen, J., 1587
 Penicaud, L., 685
 Penn, M.S., (Suppl. 2) 61
 Penny, M.A., 914
 Perico, N., 533
 Permutt, M.A., 685, 742, 807, 843, 1367, 1496, 1660
 Perseghin, G., 1632
 Persson, A., 946
 Pessin, J.E., 1436
 Petersen, J.S., 1355
 Pettitt, D.J., 235, 1141
 Pfeifer, M., 430
 Phatak, R.B., (Suppl. 2) 124
 Phillips, L.S., 835
 Planese, L., 521
 Piccinelli, A., 533
 Pizzo, P., 408
 Pleasic, S.M., 183
 Ploug, T., 215
 Podesta, F., 1009
 Polonsky, K.S., 368, 392, 1346
 Polvi, S., 1528
 Porcellini, A., 521
 Posselt, A.M., 771
 Poulin, R.A., 241
 Pouliot, M.-C., 826
 Poussier, P., 1617
 Pozza, G., 1632
 Pozzilli, P., 1640
 Prato, S.D., 1151
 Pratten, M.K., 318
 Press, M., 17
 Pressel, D.M., 662, 1221
 Prochazka, M., 98
 Province, M.A., 843
 Prud'homme, D., 826
 Pugh, W., 1308
 Pugliese, A., 347, 788
 Pujol-Borrell, R., 1624

R

Raben, N., 408
 Rabin, D.U., 183, 807
 Raheja, B.S., (Suppl. 2) 124
 Raikhel, I., (Suppl. 2) 126
 Rajotte, R.V., 114, 1172
 Rand, L.I., 430
 Randolph, A.L., 222
 Rapp, J.H., 325
 Reaven, G.M., 1547
 Remuzzi, G., 533
 Riccardi, G., 521
 Riccio, A., 968
 Rich, S.S., 850
 Richter, E.A., 174
 Riley, W.J., 879
 Rinaldi, G.J., 30
 Rivier, J., 17
 Robertson, D.G., 835
 Robertson, R.P., 1, 1390
 Roep, B.O., 1380
 Rög, M., 533
 Roger, M., 1385
 Rohner-Jeanrenaud, F., 493
 Roques, M., 451
 Rosenzweig, S.A., 818
 Rosner, B., 850
 Rossen, P., (Suppl. 2) 127
 Rossetti, L., 1453
 Roth, J., 408, 855
 Roth, M.-P., 879
 Rothlein, R., 1668
 Rotter, J.I., 879
 Rowley, M.J., 548
 Rudolph, S., 927
 Rumley, A., 909
 Rumley, A.G., 909
 Russell, D., 359
 Ryan, C.M., 107

S

Saad, M.F., 1141
 Sacerdoti, D., 936
 Saint-Paul, M., 1385
 Saitoh, T., 1409
 Saitoh, Y., 1422
 Sakakibara, F., 587
 Sakamoto, N., 587, (Suppl. 2) 126
 Salković, M., 1119
 Sambataro, M., 936
 Samols, E., 93
 Sandison, A., 952
 Sanmarti, A., 1624
 Santamaria, P., 53
 Sato, Y., 438
 Saudek, C.D., 657
 Saunders, J.K., 1328
 Savage, P.J., (Suppl. 2) 4
 Savin, V.J., 1106
 Schafer, W., (Suppl. 2) 127
 Schalin-Jäntti, C., 598
 Schambelan, M., 1113

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

- Scharp, D.W., 662
 Schmalbruch, H., 215
 Schneider, D.J., 890
 Schrier, R.W., 1464
 Schröder-van der Elst, J.P., 147
 Schumacher, M.C., 416
 Seaquist, E.R., 1390
 Secchi, A., 1632
 Sechi, L.A., 1113
 Segal, K.R., 1257
 Seino, S., 76, 1436
 Seino, Y., 76, 592, 861, 1555
 Sell, D.R., 153, 1286, (Suppl. 2) 36
 Sens, D.A., 1050
 Seo, T.S., 1436
 Seow, W.K., 616
 Serie, J.R., 1122
 Serreze, D.V., 98, 1672
 Sesti, G., 6
 Shafer, D., (Suppl. 2) 18
 Shal, Y., 855
 Shamoon, H., 1335
 Shank, M.L., 1151
 Shapiro, J.A., 183
 Shattock, M., 782
 Shaw, J.A.G., 1496
 Shechter, Y., 982
 Sheehy, M.J., 123
 Shelley, D.R., 1257
 Shepherd, P.R., 1360
 Sheppard, M.C., 35
 Sheppard, P.O., 82
 Sherwin, R.S., 17, 691
 Shiffman, A.J., 347
 Shigeta, Y., 476, 1165, (Suppl. 2) 126, 128
 Shirato, I., 1520
 Shisheva, A., 982
 Shishko, P.I., 1042
 Shoger, K.D., 1390
 Shojaaee, N., (Suppl. 2) 81
 Shulman, G.I., 691
 Sidhu, M., 1341
 Simmons, D., 760
 Simon, D., 1385
 Simonson, D.C., 1597
 Singer, D.E., 202
 Singh, B., 114
 Sipos, G.F., 872
 Sixma, J.J., (Suppl. 2) 127
 Sklar, A.H., 627
 Sködt, P., 174
 Slavin, B., (Suppl. 2) 124
 Sleeman, M.W., 1446
 Slieker, L.J., 187
 Small, M., 909
 Smith, R.M., 194, 792
 Smith, U., 294, 707
 Sobel, B.E., 890
 Sobel, D.O., 515, 1016
 Sobis, H., 1491
 Sochor, M., 1429
 Soeldner, J.S., 347, 850
 Solders, G., 946
 Soldevila, G., 1624
 Soler, A.P., 194
 Solini, A., 1151
 Sollberg, S., 1587
 Solomon, B.A., 886
 Someya, Y., 592
 Somoza, N., 1624
 Sørensen, K.E., 812
 Sorensen, L.K., 648
 Sorkin, J., (Suppl. 2) 122
 Sorrentino, R., 904
 Soulis-Liparota, T., (Suppl. 2) 123
 Spanheimer, R.G., 222
 Sparkes, R.S., 879
 Spire, J.-P., 392
 Sportsman, J.R., 187
 Spotti, D., 1632
 Srinivasan, S.R., 313
 Staedel, C., 451
 Stagner, J.L., 93
 Staprans, I., 325
 Staudacher, C., 1632
 Steele, J.S., (Suppl. 2) 125
 Steffes, M.W., 581, 679
 Steinhart, C.M., 627
 Stern, M.P., 484, 715, 1267, 1575
 Stocks, J., 1640
 Stolpe, M., 975
 Strielemann, P.J., 989
 Sturis, J., 368, 392, 1346
 Sturman, J.A., 1130
 Subieta, A.R., 160
 Sullivan, S.J., 886, 1503
 Sundell, K.L., 187
 Sundkvist, G., 1022
 Sundler, F., 130
 Sutherland, D.E.R., 53, 679
 Sutherland, E., 1328
 Sutherland, G.R., 1328
 Suzuki, S., 1373
 Svec, F., 133
 Svedberg, J., 294
 Sweetland, M.A., 552
- T**
- Taborsky, G.J., Jr., 82
 Tahvanainen, K., 1069
 Takuyama, Y., 1409
 Tal, M., 792
 Tamborlane, W.V., 17
 Taminato, T., 1555
 Taneda, Y., 1373
 Taniguchi, A., 1540
 Tanizawa, Y., 685, 807, 1367
 Tariq, T., 1239
 Taskinen, M.-R., (Suppl. 2) 12
 Tavella, M., (Suppl. 2) 18
 Taylor, M., 648
 Taylor, R.P., 1056
 Taylor, S.I., 408, 1473
 Territo, M., (Suppl. 2) 74
 Theret, N., (Suppl. 2) 81
 Thistlethwaite, J.R., 1346
 Thomaseth, K., 633
 Thompson, M.J., (Suppl. 2) 121
 Thong, Y.H., 616
 Thorens, B., 1320
 Thorer, M., 17
 Thorpe, S.R., (Suppl. 2) 42
 Tiengo, A., 968
 Tilton, R.G., 552
 Tobin, B.L., 1172
 Tobin, B.W., 1172
 Todd, J.A., 1029
 Tokuyama, K., 1540
 Tokuyama, Y., 1409
 Tomino, Y., 1520
 Tosi, R., 904
 Towle, V.L., 392
 Town, E., 318
 Toyota, T., 1373, (Suppl. 2) 126
 Tozzo, E., 1609
 Trachtman, H., 1130
 Travers, J.P., 318
 Tremblay, A., 826
 Trevisan, R., 1239
 Triban, C., 866
 Trucco, G.A., 616
 Tschoepe, D., (Suppl. 2) 127
 Tsilibary, E.C., (Suppl. 2) 49
 Tsuji, K., 76, 861, 1555
 Tsukuda, K., 22
 Tsuura, Y., 861, 1555
 Tun, R.Y.M., 782
 Turner, R.C., 962, 1160, 1496
 Tybjaerg-Hansen, A., 962
 Tydén, G., 946
 Tyson, R., 1328
- U**
- Uchimura, I., (Suppl. 2) 128
 Uhing, M.R., 1644
 Ulitto, J., 1587
 Ullrich, A., 6
 Umeda, F., 723
 Umemura, K., 1165
 Unger, R.H., 508, 1278
 Uusitupa, M., 1069
- V**
- The VA Cooperative Study Group on
 Diabetes Mellitus, (Suppl. 2) 123
 Vaag, A., 174
 Vadheim, C.M., 879
 Valdez, R.A., 715
 Vale, W., 17
 Valerio, A., 968
 Valleria, D.A., 457
 Valyou, P.M., 1091
 van Beers, W.A.M., 1570
 van Cauter, E., 368, 1346
 Vandeputte, M., 1491
 van der Heide, D., 147
 Vandongen, R., 261

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676

Vanninen, E., 1069
 Varrone, S., 521
 Vergani, S., 1632
 Viberti, G., 610, 736, 1239
 Vichi, M., 1009
 Vigeant, C., 1273
 Villafuerte, B.C., 835
 Villalpando, E., 484
 Vilstrup, H., 12
 Virella, G., (Suppl. 2) 86
 Vives, M., 1624
 Vlassara, H., (Suppl. 2) 52
 Vlassara, J., (Suppl. 2) 125
 Vranic, M., 1188, 1562
 Vuorinen-Markkola, H., 571

W

Waer, M., 1491
 Wainscoat, J.S., 962
 Walker, J.D., 1239
 Walker, M., 1400
 Walseth, T.F., 1390
 Walton, C., 1341
 Wang, J.L., 552
 Wang, T., 114
 Ward, G.M., 1446
 Warnock, G.L., 114
 Warram, J.H., 430, 850
 Wasserman, D.H., 1229
 Waters, S.H., 308
 Ways, J., 118
 Weinstein, S.P., 728
 Weir, G.C., 1320
 Welling, C.M., 742, 807

Welty, T.K., (Suppl. 2) 4
 Werther, G.A., 499
 Wesslau, C., 1360
 Widén, E.I.M., 354
 Widom, B., 1597
 Wiegmann, T.B., 62, 1035, 1106
 Wiegner, A., 385
 Williams, B., 1464
 Williams, G., 209
 Williams, R.R., 416
 Williams, T.M., 107
 Williamson, J.R., 552
 Wilson, P.W.F., 202
 Winocour, P.D., (Suppl. 2) 26
 Witzum, J.L., (Suppl. 2) 125
 Wohltmann, H.J., 1301
 Wolny, J.D., 1084
 Wright, E.M., 766
 Wright, J.R., Jr., 1528
 Wroblewski, V.J., 539
 Wynn, V., 1341
 Wynne, H.J., (Suppl. 2) 127

X

Xiang, K.-S., 401

Y

Yadav, J.N., (Suppl. 2) 124
 Yagihashi, N., 47
 Yagihashi, S., 47
 Yale, J.-F., 1273

Yamada, N., (Suppl. 2) 126
 Yamada, T., 438
 Yamada, Y., 76
 Yamaguchi, T., 1409
 Yamaguchi, Y., 1570
 Yamamoto-Honda, R., 1373
 Yamamura, K.-I., 1409
 Yamaoka, T., 956
 Yamashita, K., 956
 Yang, S.-D., 68
 Yang, Y.J., 241
 Yano, H., 76, 592
 Yasuda, K., 76, 592, 1436
 Yazaki, Y., 22
 Yeh, J., (Suppl. 2) 4
 Yeung, V.T.F., 914
 Yki-Järvinen, H., 571
 Yoon, J.-W., 998
 Yoshida, S., 1409
 Yost, T.J., 641
 Youn, J.H., 872
 Yudkin, J.S., 167, (Suppl. 2) 124
 Yui, K., (Suppl. 2) 128
 Yunis, E.J., 788
 Yutani, C., (Suppl. 2) 126

Z

Zajarny, I.U., 1042
 Zatz, R., 286
 Zelig, B.J., 1016
 Zetterström, C., 818
 Zimmerman, E.C., 792
 Zimmet, P.Z., 548
 Zinman, B., 227
 Zolli, M., 968

DIABETES: VOLUME 41 (1992) PAGE NUMBERS BY ISSUE

January, 1-121
 February, 123-253
 March, 255-399

April, 401-556
 May, 557-656
 June, 657-775

July, 777-895
 August, 897-1027
 September, 1029-1219

October, 1221-1365
 November, 1367-1501
 December, 1503-1676